Zymeworks (ZYME) Cash from Investing Activities Growth (1y) (2022 - 2026)

Zymeworks (ZYME) Cash from Investing Activities Growth (1y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 62.68%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -674.01%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -166.24%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Zymeworks 1.73 Bn 1.36 Bn - 474.28%

Historic Data

Download Data
DateValue
Mar 31, 2026 474.28%
Dec 31, 2025 186.39%
Sep 30, 2025 -99.49%
Jun 30, 2025 143.79%
Mar 31, 2025 266.51%
Dec 31, 2024 -364.77%
Sep 30, 2024 1,129.30%
Jun 30, 2024 67.08%
Mar 31, 2024 94.71%
Dec 31, 2023 93.94%
Sep 30, 2023 76.93%
Jun 30, 2023 -176.67%
Mar 31, 2023 -771.83%
Dec 31, 2022 -1,088.21%